Natalizumab for active Crohn's disease.

By Subrata Ghosh, E. Goldin, F. Gordon, H. Malchow, J. Rask-Madsen, P. Rutgeerts, P. Vyhnálek, Z. Zádorová, T. Palmer, S. Donoghue. New England Journal of Medicine, 2003

768 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/45a491b43b7318df857dd0ca0b749a7815eedcf7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. R. Sartor
2. W. Strober

In Genetics

1. R. Sartor
2. W. Strober
3. J. Turner

In Immunology

1. R. Sartor
2. A. Luster
3. Ulrich H. von Andrian
4. R. Alon
5. W. Strober

Citations in the corpus

• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. (2006, neutral): “…(Yednock et al., 1992), clinical trials with Natalizumab , a humanized monoclonal antibody directed against the a4 integrin of the adhesion molecule VLA- 4, were conducted, and very encouraging results were reported in both MS (O'Connor et al., 2004) and Crohn's disease (Ghosh et al., 2003).”
• Immune cell migration in inflammation: present and future therapeutic targets (2005, background): “Furthermore, Natalizumab is very efficacious in Crohn diseas”
• The immunological and genetic basis of inflammatory bowel disease (2003, background): “In fact, treatment with antibodies specific for molecules that are involved in mucosal-specific migration, such as the integrin α4β7, has already been shown to have some therapeutic valu”
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis (2006, background): “Monoclonal antibody to integrin-α 4 (natalizumab), which binds both intergrin-α 4 β 7 (the MAdCAM1 ligand) and integrin-α 4 β 1 (the VLA4 ligand), is effective in treating Crohn's disease”